Cargando…
Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
BACKGROUND: The most common genetic changes identified in human NSCLC are Kras mutations (10–30 %) and p53 mutation or loss (50–70 %). Moreover, NSCLC with mutations in Kras and p53 poorly respond to current therapies, so we are trying to find a new target for the treatment strategies. METHODS: Flow...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755025/ https://www.ncbi.nlm.nih.gov/pubmed/26884725 http://dx.doi.org/10.1186/s12935-016-0280-y |